Navigation Links
SK Life Sciences has Licensed Pristima

Xybion Medical Systems, is pleased to announce that SK Life Science, Inc. (SKLSI), has licensed Pristima for its Research and Development facility in Fair Lawn, New Jersey.

Cedar Knolls, NJ (PRWEB) August 3, 2009 -- Xybion Medical Systems, a world leader in toxicology and pathology data management solutions and the developer of Pristima™ the premier preclinical solution on the market, is pleased to announce that SK Life Science, Inc. (SKLSI), has licensed Pristima for its Research and Development facility in Fair Lawn, New Jersey.

After extensive research and evaluation of the products on the market, SKLSI selected Xybion's Pristima to manage its general toxicology data as well as licensing Xybion's Standard Validation Package and contracting Xybion to perform the full suite of installation, training and validation execution services. Additionally, SKLSI has contracted to have Xybion's professional services team perform all of the hardware installation, third-party software installation and all other IT services related to Pristima.

Dr. Pradip Banerjee, Xybion's CEO, stated that "we are proud to add SK Life Science, Inc., another leading global research and development company to our growing community. We are tremendously satisfied that SKLSI has acknowledged Pristima to be the most powerful system on the market. Pristima is designed to account for all types of toxicology studies and is specifically well-suited to collect, manage and summarize data for global pharmaceutical and chemical companies as well as contract research organizations."

Dr. Hong Wook Kim, Director, Non-clinical Development of SK Life Science, Inc., remarked that "SKLSI is building its research and development arm and required the most modern toolset in order to address current and future projects."

About SK Life Sciences - SK Life Science, Inc. (, US subsidiary of SK Holdings, Co., Ltd., one of the largest conglomerate and the leading energy and chemical company in Korea, has been engaged in the innovative discovery and development of novel therapeutic compounds in the field of neuroscience in order to treat CNS disorders including epilepsy, depression, anxiety, schizophrenia, Parkinson's disease, and other neurodegenerative disorders. In addition to the CNS area of research, SK Life Science is working on the discovery and development of novel therapeutic compounds for the treatment of metabolic diseases.

About Xybion Medical Systems - Xybion ( is the enterprise system partner of choice for life sciences product companies and research organizations worldwide. In addition to the Pristima Data Management suite, Xybion provides professional services, consulting, training and validation activities to clients throughout the world.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Human Genome Sciences Announces Closing of Public Offering
2. Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
3. Caliper Life Sciences Reports Second Quarter 2009 Results
4. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
5. Neurocrine Biosciences Reports Second Quarter 2009 Results
6. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
7. Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
8. SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production
9. Human Genome Sciences Announces Pricing of Public Offering of Common Stock
10. Human Genome Sciences Announces Proposed Public Offering of Common Stock
11. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) ... USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes ... with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of ...
(Date:11/24/2015)... ... 24, 2015 , ... Copper is an essential micronutrient that ... proteins, copper is also toxic to cells. With a $1.3 million award from ... conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):